Printer Friendly
The Free Library
4,631,108 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Browse RNA interference topic

Subtopics (18)

 

Articles

1-100 out of 100 article(s)
Title Author Type Date Words
IMM, Cenix, and Alnylam Discover New Targets in Malaria Infection with RNAi Technology. Nov 11, 2008 1415
Alnylam and Collaborators Publish Research on a New Class of Chemically Modified RNAi Therapeutics that Target Two Distinct Cellular Mechanisms. Nov 3, 2008 1305
Anastasia Khvorova, Ph.D., a Leading Scientist in the RNAi Industry, Joins RXi Pharmaceuticals as Chief Scientific Officer. Oct 22, 2008 704
Dicerna Pharmaceuticals, an RNA Interference Company, to Present at Discovery on Target Conference. Conference news Oct 22, 2008 609
CytRx Corporation's 45% Owned Affiliate RXi Pharmaceuticals Obtains an Exclusive Worldwide License to Technology for the Oral Delivery of RNAi Therapeutics from the University of Massachusetts Medical School. Oct 15, 2008 865
RXi Pharmaceuticals Obtains an Exclusive Worldwide License to Technology for the Oral Delivery of RNAi Therapeutics from the University of Massachusetts Medical School. Oct 14, 2008 745
Alnylam Forms Collaboration with Max Planck Institute to Investigate Biological Mechanisms for Cellular Uptake of RNAi Therapeutics. Aug 11, 2008 1016
Alnylam Awarded Continued Funding Under U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats. Aug 6, 2008 1287
Alnylam Grants New InterfeRx(TM) Intellectual Property License to Calando for Development and Commercialization of RNAi Therapeutics. Jul 21, 2008 1066
Alnylam Announces Extension of RNAi Therapeutics Collaboration with Novartis. Jul 16, 2008 902
Dicerna Pharmaceuticals, a Second Generation RNA Interference Company, Completes Second Closing of Series A Financing; Unveils Strategic Focus. Jul 15, 2008 844
Thermo steps up RNAi market presence. Jul 15, 2008 145
Apoptosis and pathogenesis of melanoma and nonmelanoma skin cancer. Report Jul 1, 2008 405
Silence Receives Allowance for its Core RNAi Patent. Jul 1, 2008 858
Thermo Fisher Scientific Acquires Open Biosystems, Creating Unmatched RNAi Platform. Jul 1, 2008 521
Dicerna Pharmaceuticals, a RNA Interference Company, to Present at 9th Annual Beyond Genome Conference. Conference news Jun 9, 2008 372
Intradigm Announces Allowance of Key RNA Interference Patent Patent Covers Small Interfering RNA Structural Features Tied to Increased Efficacy and Potency of RNAi Therapeutics. Jun 1, 2008 797
Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics. May 27, 2008 1555
Alnylam and Collaborators Publish In Vivo Research on Validation of a Mammalian Host Gene Involved in Malaria Infection and on the Anti-Parasitic Efficacy of RNAi Therapeutics. May 21, 2008 1128
Calando Granted Broad Patent Rights to RNAi Technology in China. May 13, 2008 833
Alnylam and Collaborators at MIT Publish Research on the Discovery of 'Lipidoids', a Novel Class of Lipid-Based Molecules for the Delivery of RNAi Therapeutics. Apr 28, 2008 1522
RNAi Efficacy Against ALS (Lou Gehrig's Disease) in a Research Model Published in Peer-Reviewed Journal; RXi Pharmaceuticals Exclusive Licensee of Research. Apr 10, 2008 805
Nastech Pharmaceutical Company Inc. to Present RNAi Data. Mar 25, 2008 843
RXi Pharmaceuticals to Present Data on the Cellular Mechanism of RNAi Interference at Keystone Symposia's RNAi, MicroRNA, and Non-Coding RNA Meeting. Mar 20, 2008 571
Alnylam Grants Shanghai GenePharma License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market. Mar 20, 2008 1096
RNAi dispute resolved. Mar 15, 2008 79
Nastech Pharmaceutical Company Inc. Completes Key RNAi Patent Filings. Mar 11, 2008 907
Nastech Pharmaceutical Company Inc. Announces Scientific Advisory Board for MDRNA, Inc., its Wholly-Owned RNAi Subsidiary. Mar 7, 2008 1431
Alnylam Achieves First Human Proof of Concept for an RNAi Therapeutic with GEMINI Study. Feb 29, 2008 1692
Rxi Pharmaceuticals exclusively licensed certain RNAi sequences. Feb 29, 2008 11
Alnylam to Webcast Conference Call to Discuss Phase II GEMINI Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection. Feb 25, 2008 430
Alnylam Reports Pre-clinical Progress with RNAi Therapeutics in Neurological Disease. Feb 7, 2008 1043
Traversa Raises $2M to Advance RNAi Delivery in Angel-Led Series A Financing. Feb 4, 2008 552
Intradigm Strengthens RNA Interference (RNAi) Position with MIT License. Feb 1, 2008 434
SuperArray Bioscience licensed RNAi patents. Jan 31, 2008 9
Alnylam Announces Grant of New Patent Covering RNAi Therapeutics in the United Kingdom. Jan 28, 2008 1717
Alnylam Reports Positive Phase II Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection. Jan 23, 2008 1089
Alnylam Launches its RNAi 2010 Outlook for Key Scientific, Clinical, and Business Initiatives; Announces Goals and Guidance for 2008. Jan 7, 2008 1822
Alnylam Announces Continued Progress on Development of its Intellectual Property Estate Covering RNAi Therapeutics. Jan 3, 2008 1762
Promega increased its stake in RNAi provider Benetec to 6.15%. Dec 15, 2007 20
RXi Pharmaceuticals Licenses Rights to RNAi Sequences to Genes for Therapeutic Applications from Thermo Fisher Scientific. Dec 14, 2007 915
Alnylam Announces Grant of Broad Patent Covering RNAi Therapeutics in Germany. Nov 26, 2007 1584
Invitrogen and CytRx Subsidiary RXi Pharmaceuticals Collaborate to Enhance RNAi Technologies for Therapeutic Applications. Nov 14, 2007 918
SuperArray Bioscience licenses RNA interference patent from The Carnegie Institution. Nov 1, 2007 398
Alnylam and Collaborators Publish New Pre-clinical Results on RNAi Therapeutics for the Treatment of Huntington's Disease. Oct 17, 2007 1007
Alnylam Presents First Ever Non-Human Primate Data with an RNAi Therapeutic Targeting PCSK9 Showing Significant and Durable Reductions in LDL Cholesterol Levels. Oct 8, 2007 1415
Alnylam Grants GeneDesign License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market. Oct 3, 2007 990
Alnylam and Collaborators Publish New Paper in the Journal Nature on the In Vivo Efficacy and Safety of RNAi Therapeutics. Sep 26, 2007 1049
Alnylam and Collaborators Publish New Research on the In Vivo Mechanisms for Systemic Delivery of RNAi Therapeutics. Sep 17, 2007 1112
Alnylam Pharmaceutical granted Hayahi Kasei a license to provide RNAi. Sep 15, 2007 19
Patent Application Licensed to RXi Pharmaceuticals Issues in Australia with Broad Claims to Expressed RNAi. Sep 5, 2007 575
Patent Application Licensed to CytRx Subsidiary RXi Pharmaceuticals Issues in Australia With Broad Claims to Expressed RNAi. Sep 5, 2007 805
Mello promotes RNAi research; Nobel Prize winner says tool would revolutionize medicine. Aug 9, 2007 530
Alnylam Awarded $38.6 Million U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats. Aug 9, 2007 1242
Quark files patent application covering chemical modifications to its RNAi molecules. Aug 1, 2007 431
Alnylam and Medtronic Advance Collaboration on Drug-Device Combinations with RNAi Therapeutics for CNS Diseases. Jul 30, 2007 1109
Examine the Outlook for RNAi, 2007: siRNA and miRNA in Biology, Diagnostics and Therapeutics. Jul 20, 2007 563
Alnylam Grants Hayashi Kasei License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market. Jul 19, 2007 979
Kylin Therapeutics Licenses an RNAi Delivery Technology from Purdue University. Jul 9, 2007 389
Roche and Alnylam Form Major Alliance on RNAi Therapeutics. Jul 9, 2007 1518
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Dmitry Samarsky, Ph.D., as Vice President of Technology Development. Jun 26, 2007 932
Delivering RNAi; UMass Med School doctor combines nanotechnology and gene silencing. May 28, 2007 1170
Alnylam Establishes New Research Program on Delivery of RNAi Therapeutics at MIT's Center for Cancer Research. May 9, 2007 994
CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal. Apr 23, 2007 1103
Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer. Apr 17, 2007 1376
Alnylam granted Bio-Rad Laboratories a license to provide RNAi research products. Apr 15, 2007 16
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Leader in RNAi Therapeutics to Its Scientific Advisory Board. Apr 9, 2007 961
Alnylam Grants Bio-Rad License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market. Mar 29, 2007 907
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Announces Worldwide Research and Therapeutic RNAi Licensing Agreement with Cold Spring Harbor Laboratory. Mar 19, 2007 908
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Vice President of Pharmaceutical Development. Mar 8, 2007 890
INEX and Alnylam Announce Allowance of New U.S. Patent Covering Delivery of RNAi Therapeutics. Mar 7, 2007 1199
CytRx RNAi Subsidiary RXi Pharmaceuticals Forms Board of Directors. Feb 27, 2007 1366
CytRx Subsidiary, RXi Pharmaceutical Corp., Enters into Scientific Advisory Board Agreements with Key RNAi Scientists. Feb 26, 2007 683
RNAi Shows Promise in Gene Therapy, Stanford Researcher Says. Feb 18, 2007 426
Rnai Is By Far The Most Widely Used Gene-Silencing Technique Employed In Research. Feb 12, 2007 468
Alnylam Presents Pre-clinical Results from Hypercholesterolemia, Huntington's Disease and Neuropathic Pain Programs at Keystone Symposium on RNAi. Feb 1, 2007 1338
CEO of CytRx Subsidiary, RXi Pharmaceuticals, to Participate on RNAi Panel at Mass High Tech BioForum. Jan 29, 2007 606
Profiles of 75 Companies Involved in Developing RNAi Technologies are Presented Inside the 2007 Edition of RNAi - Technologies, Markets and Companies. Jan 24, 2007 695
CytRx Corporation Subsidiary, RXi Pharmaceuticals, Obtains Option to License All Unrestricted Therapeutic RNAi Technologies Developed in the Next Three Years by the University of Massachusetts Medical School. Jan 16, 2007 1053
CytRx creates subsidiary for gene-silencing technology: RXi will focus on RNAi interference for treatment of diseases. Crowe, Deborah Jan 15, 2007 398
CytRx Corporation Subsidiary, RXi Pharmaceuticals, Licenses "Nanotransporters" and Other RNAi Discoveries from the University of Massachusetts Medical School. Jan 11, 2007 1209
CytRx forms RNAi company, enlists UMass advisory team. Jan 10, 2007 915
Alnylam and Inex Form Strategic Technology Alliance to Discover and Develop RNAi Therapeutics with Lipid-Based Delivery Formulations. Jan 9, 2007 1462
CytRx Corporation Establishes RNAi Subsidiary, RXi Pharmaceuticals. Jan 9, 2007 1739
Geneservice gained an exclusive license to distribute the pSUPER RNAi vector system and pRETROSUPER vector-based shRNA. Dec 31, 2006 25
Alnylam Advances a Systemically Delivered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia as New Development Program. Dec 5, 2006 1202
Mirus Bio awarded broad RNAi patent using hydrodynamic intravascular injection. Dec 1, 2006 542
Alnylam Initiates Clinical Program to Evaluate Anti-Viral Activity for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection. Nov 28, 2006 1206
GeneThera to Advance RNA Interference Work Through Collaboration Agreement. Nov 8, 2006 588
Alnylam and Yale University Scientists Demonstrate Therapeutic Silencing of Disease Target Associated with Acute Lung Injury Using RNAi. Nov 6, 2006 1166
Alnylam Announces Progress in Pre-Clinical Hypercholesterolemia RNAi Therapeutic and microRNA Programs. Oct 23, 2006 1396
Alnylam Initiates Phase I Clinical Study of Inhaled Formulation of ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection. Oct 11, 2006 1313
Alnylam Notified of Defense Appropriation Funding for Ongoing Development of RNAi Therapeutics. Oct 4, 2006 783
CytRx Scientific Advisory Board Member Dr. Craig C. Mello Awarded Nobel Prize in Medicine for RNAi Discovery. Oct 3, 2006 1230
Abbott and Fisher Biosciences' Dharmacon unit are collaborating to develop new therapeutic agents based on RNAi. Sep 30, 2006 22
Alnylam Awarded $23 Million U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats. Sep 28, 2006 1063
Alnylam Grants Quark a License to Develop and Commercialize Two RNAi Therapeutic Products. Sep 26, 2006 1662
Biogen Idec and Alnylam Form Alliance to Discover and Develop Therapeutics for the Potential Treatment of Progressive Multifocal Leukoencephalopathy (PML); Collaboration to Focus on RNAi Therapeutics Targeting the JC Virus. Sep 20, 2006 1285
Open Biosystems Helps Drexel University ''Knock Out'' Genes Associated with Alzheimer's Disease; Drexel's RNAi Resource Center Relies on Open Biosystems' Comprehensive Expression Arrest(TM) shRNAmir Retroviral Library to Advance Research Efforts. Sep 18, 2006 588
Under a co-exclusive multiyear alliance, VWR will support RNAx GmbH's automated RNAi validation services. Aug 31, 2006 25

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles